Ulysses Neuroscience Ltd is a patient-centric private R&D organization working together with pharmaceutical companies in order to accelerate drug discovery in neuropsychiatric (major depression, anorexia nervosa and schizophrenia) and neurodevelopmental (Fragile X Syndrome and CDKL5 Deficiency Disorders) diseases by using translation clinical and pre-clinical research. Our translational research investigates neurophysiological and molecular mechanisms leading to the synaptic pathology, microtubule dynamics dysregulation and neuroinflammatory events.
Eurofins BioPharma Product Testing (BPT) delivers a broad range of harmonized methodologies under GMP authorization and certification. We offer R&D services for method development of analytical methods suitable for GMP Chemistry and Microbiology testing and certification of raw materials and finished products. Our 30,000 ft2 laboratory is equipped with state of the art analytical instrumentation and includes a sterility suite, a wide array of stability chambers as well as an extensive controlled drug substance license and narcotics vault.
Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.